#United States #Miami #opioid use disorder #Buprenorphine #BRIXADI

Introduction

Braeburn Inc. has made significant strides in addressing opioid use disorder (OUD) with its advanced medication, BRIXADI, as evident during the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting held in Miami, Florida, in May 2026. The company showcased compelling new data regarding the effectiveness of BRIXADI, particularly focusing on its use at low plasma concentrations of buprenorphine for opioid withdrawal suppression.

Key Findings

During the meeting, three critical posters were presented that highlight the clinical efficacy of weekly and monthly injectable BRIXADI. These findings are paramount in understanding how this treatment can be utilized effectively in real-world scenarios. Below, we delve into the details of each presented poster:

1. First Dose Treatment Effects

One of the standout posters analyzed the treatment effects of BRIXADI at administering a single dose (32 mg for weekly and 128 mg for monthly) focusing on the relationship between buprenorphine plasma concentrations and withdrawal suppression. In a post-hoc analysis involving 110 participants, it was revealed that withdrawal symptoms were significantly managed even with plasma concentrations falling below 0.5 ng/mL. This observation indicated that effective withdrawal suppression was achieved consistently, suggesting a minimal dependency on high plasma levels for effective treatment response.

2. Real-World Utilization Trends

Another poster provided insights from a retrospective analysis of data collected from specialty pharmacies across the United States. This analysis encompassed over 30,000 patients and outlined how BRIXADI is dispensed in various dosing regimens. Utilization data reflected that the majority of patients opted for both weekly and monthly doses, signifying the medication's adaptable dosing options. Notably, approximately 60.8% of participants who began on weekly doses transitioned to a monthly dosing regimen over time, aligning with clinical guidelines that endorse tailored treatment strategies based on individual needs.

3. Treatment Retention Comparison

The final poster compared treatment retention rates among patients using BRIXADI and those using sublingual buprenorphine, particularly focusing on individuals with recent fentanyl exposure. The study, which evaluated 648 patients across national outpatient addiction clinics, found that those treated with BRIXADI exhibited significantly higher retention rates over six months—their retention was notably better at critical time junctures (e.g., Day 30, Day 90, Day 180). This suggests that BRIXADI could potentially lead to better management of OUD in patients at risk due to concurrent substance use.

Expert Commentary

Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer at Braeburn, emphasized the importance of these findings. He remarked, "For too long, treatment decisions have been influenced by older studies that might not fully reflect how buprenorphine can be effectively utilized in today’s evolving opioid crisis context." Cohen highlighted that such data plays a critical role in refining treatment approaches and encourages the adoption of personalized medication management strategies for those combating opioid addiction.

Conclusion

As Braeburn continues to push forward with its research and development efforts on BRIXADI, these presentations at the ASCP Annual Meeting exemplify the potential for improving treatment protocols for individuals affected by opioid use disorder. With its low dosing strategies exhibiting effective withdrawal suppression, BRIXADI demonstrates a promising avenue for fostering recovery and addressing the ongoing opioid crisis. The findings shared at the meeting not only contribute valuable insights into treatment but also reinforce the urgent need for advances in therapeutic approaches tailored to the unique challenges posed by today's opioid epidemic. As more clinicians become aware of these developments, it is hoped that patient outcomes will improve significantly in the near future.